IPSC Century Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850119 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,556.5%
TTM net income YoY92.4%
TTM EPS YoY91.3%
Revenue 3-yr CAGR175.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-15.8%
Net margin-8.8%
FCF margin-95.9%
EBITDA margin-3.8%
Returns
ROE-6.0%
ROA-3.3%
ROIC (approx.)-13.8%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets29.0%
Debt / equity0.00x
Current ratio5.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income10.85x
Accruals ratio32.7%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $109.16M | $4.17M |
| R&D expense | $18.06M | $19.59M | $17.11M | $19.70M | $22.53M | $26.86M | $26.58M | $29.38M |
| SG&A expense | $7.15M | $5.79M | $6.58M | $956,000 | $6.83M | $7.80M | $8.41M | $7.75M |
| Operating income | -$25.21M | -$36.53M | -$23.68M | -$20.65M | -$36.12M | -$34.66M | $74.18M | -$37.28M |
| Pretax income | — | — | — | -$19.24M | -$34.42M | -$32.54M | $76.56M | -$34.30M |
| Income tax | — | — | — | — | — | — | — | $1.78M |
| Net income | -$23.45M | -$34.55M | -$21.64M | -$19.17M | -$34.42M | -$32.54M | $76.56M | -$36.07M |
| EBITDA | -$23.02M | -$36.50M | -$20.68M | -$17.10M | -$32.99M | -$31.46M | $77.40M | -$33.97M |
| EPS (basic) | -0.11 | -0.17 | -0.11 | — | -0.40 | -0.38 | 0.89 | — |
| EPS (diluted) | -0.11 | -0.17 | -0.11 | — | -0.40 | -0.38 | 0.89 | — |
| Weighted avg. shares (diluted) | 206.44M | 205.78M | 193.47M | — | 86.46M | 86.24M | 86.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $45.02M | $49.64M | $51.05M | $61.85M | $58.67M | $59.59M | $54.64M | $61.21M |
| Short-term investments | $72.19M | $70.07M | $83.75M | $55.26M | $77.23M | $98.97M | $113.26M | $130.85M |
| Current assets | $122.71M | $124.77M | $139.04M | $120.77M | $137.71M | $160.17M | $169.63M | $194.05M |
| PP&E, net | $32.83M | $34.48M | $47.61M | $50.03M | $53.72M | $56.65M | $59.53M | $62.14M |
| Intangibles | $34.20M | $34.20M | $34.20M | $34.20M | $34.20M | $34.20M | $34.20M | $34.20M |
| Total assets | $262.63M | $287.01M | $326.55M | $223.70M | $244.72M | $284.69M | $315.61M | $353.22M |
| Current liabilities | $14.04M | $15.07M | $13.57M | $20.23M | $22.03M | $14.95M | $14.50M | $129.78M |
| Total liabilities | $52.66M | $54.66M | $61.81M | $64.77M | $68.37M | $74.79M | $75.17M | $191.85M |
| Shareholders' equity | $209.97M | $232.34M | $264.74M | $158.94M | $176.35M | $209.90M | $240.44M | $161.36M |
| Shares outstanding | 181.24M | 180.55M | 180.10M | 87.52M | 86.53M | 86.32M | 86.15M | 85.84M |
| Cash flow statement | ||||||||
| Operating cash flow | -$22.23M | -$19.83M | -$25.26M | -$16.08M | -$25.58M | -$27.59M | -$34.62M | -$24.22M |
| Capital expenditure | $535,000 | $694,000 | $584,000 | -$139,000 | $195,000 | $317,000 | $475,000 | — |
| Free cash flow | -$22.76M | -$20.53M | -$25.85M | -$15.94M | -$25.78M | -$27.91M | -$35.10M | — |
| Investing cash flow | $17.53M | $17.77M | -$112.61M | $22.36M | $24.67M | $32.54M | $27.93M | $30.61M |
| Financing cash flow | $76,000 | $311,000 | $126.62M | $53,000 | $0 | $0 | $120,000 | -$602,000 |
| Depreciation & amortization | $2.19M | $26,000 | $3.00M | $3.55M | $3.13M | $3.20M | $3.22M | $3.32M |
| Stock-based compensation | $1.44M | $1.95M | $1.45M | $1.30M | $891,000 | $2.22M | $2.43M | $2.66M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.